What Is New With Serums and Acne in September 2026? Latest FDA and dermatology sources and Key Takeaways

As of September 2026, the main development is early evidence that multi-acid serums may improve acne treatment and help maintain results after adapalene withdrawal. FDA activity also reinforces that acne claims trigger drug rules, while benzoyl-peroxide safety concerns remain limited rather than category-wide. For readers, the practical takeaway is simple: judge a serum by its active ingredients, supporting evidence and Drug Facts label—not by the word "serum.".

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Official resources:

Read the original research from NIH — Use this page to review the original research.
Read the original research from NIH — Use this page to review the original research.

What did the latest serum trial find?
How strong is the wider serum evidence?
Ingredients matter more than the serum label
What is FDA watching?
How should readers choose and use an acne serum?

What did the latest serum trial find?

A May 2026 randomized trial compared 0.1% adapalene alone with adapalene plus a triple-acid serum. The combination reduced inflammatory pimples, clogged pores and total acne lesions more than adapalene alone, according to the Journal of Cosmetic Dermatology study. The trial also included a maintenance phase. Acne rebounded after adapalene withdrawal in the control group, but not among participants who continued the serum.

This suggests that the serum may help preserve improvement after a retinoid is stopped. The result is promising, not definitive. The study was open-label, included only 41 patients and lasted eight weeks. Adverse events were mild and temporary, but larger blinded trials are needed before the maintenance finding can guide routine care.

How strong is the wider serum evidence?

A 2025 open-label study examined a twice-daily serum containing niacinamide and multiple acids in 50 Japanese women. Among the 46 evaluable participants, acne severity, inflammatory lesions and skin texture improved significantly by week eight. That study had no blinded comparison group, and several authors disclosed consulting relationships with L'Oréal Japan.

It supports further study of multi-ingredient serums, but it cannot establish how much improvement came from the serum, natural changes or other influences. The stronger overall evidence favors combining proven acne mechanisms. A meta-analysis covering 35 randomized trials and 33,472 patients found that topical combinations generally produced the largest reductions in mild-to-moderate acne. Adapalene–benzoyl peroxide performed particularly well, while adding clindamycin did not significantly improve noninflammatory lesions over benzoyl peroxide alone.

Ingredients matter more than the serum label

"Serum" describes a product format, not a level of effectiveness. The American Academy of Dermatology supports benzoyl peroxide, topical retinoids, topical antibiotics, clascoterone, salicylic acid and azelaic acid, while favoring combinations that attack acne through different mechanisms in its current acne guideline. That means a lightweight bottle labeled "clarifying" is not automatically an acne treatment.

Compare its active ingredient, concentration and directions with established options. For over-the-counter acne drugs, FDA's framework permits these concentration ranges: Products sold as acne drugs should identify their active ingredients in a Drug Facts panel. Front-label terms such as "purifying," "blemish control" or "clear skin" provide less useful information.

Salicylic acid: 0.5% to 2%
Benzoyl peroxide: 2.5% to 10%
Sulfur: 3% to 10%

What is FDA watching?

FDA classifies a serum promoted to treat or prevent acne as a drug, or as a drug-cosmetic combination. Ordinary skincare packaging does not remove the legal requirements created by therapeutic claims, as the agency explains in its cosmetic-versus-drug guidance. An April 2026 FDA warning letter illustrates the point. The agency warned a manufacturer that several sodium-sulfacetamide/sulfur acne products were unapproved new drugs.

Ingredient combinations and acne claims must fit a lawful marketing pathway; cosmetic wording alone is not enough. FDA also tested 95 benzoyl-peroxide acne products for benzene in 2025. Six had elevated levels, but more than 90% contained undetectable or extremely low amounts. The resulting recalls occurred at the retail level, and FDA described the cancer risk from the identified exposure as very low.

How should readers choose and use an acne serum?

Start with the treatment goal. Salicylic acid targets an established acne pathway, while adapalene and benzoyl peroxide have stronger combination evidence than serum branding itself.

Before buying, check: Multi-acid serums require particular attention to sun protection. FDA reports that alpha-hydroxy acids can increase ultraviolet sensitivity and advises sunscreen, protective clothing and limited sun exposure during use and for one week afterward, according to its alpha-hydroxy-acid guidance.

Whether the product claims to treat acne or merely improve appearance
The named active ingredient and its concentration
Whether an acne drug has a Drug Facts panel
Whether the routine duplicates acids, retinoids or other irritating products
Whether the evidence applies to people and treatment periods similar to yours